Granules India Ltd received US FDA approval for the ANDA filed for Metoprolol Succinate ER Tablets

The US Food & Drug Administration (US FDA) has approved Granules India Ltd's Abbreviated New Drug Application (ANDA) for Metoprolol Succinate ER Tablets 25/50/100/200 mg. It is therapeutically equivalent to the reference listed drug, Toprol-XL Extended-Release Tablets, 25 mg, 50 mg, 100 mg and 200 mg, of Sequel Therapeutics, LLC.

The Company had filed two ANDAs for the same product with different technologies. This is the second ANDA approval for Metoprolol Succinate ER tablets that is therapeutically equivalent to the RLD, Toprol- XL, ER tablets for Granules.

Shares of Granules India Limited was last trading in BSE at Rs. 322.85 as compared to the previous close of Rs. 320.45. The total number of shares traded during the day was 54666 in over 1204 trades.

The stock hit an intraday high of Rs. 324.75 and intraday low of 320.05. The net turnover during the day was Rs. 17646879.00.

Source : Equity Bulls

Keywords

GranulesIndia INE101D01020 USFDA ANDAApproval MetroprololSuccinateER Tablets